174 related articles for article (PubMed ID: 36891047)
1. The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer.
Wei S; Hao Y; Dong X; Huang J; Huang K; Xie Y; Liu H; Wei C; Xu J; Huang W; Dong L; Yang J
Front Endocrinol (Lausanne); 2023; 14():985858. PubMed ID: 36891047
[TBL] [Abstract][Full Text] [Related]
2. Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.
Yuan X; Wang X; Wu S; Chen S; Wang Y; Wang J; Lu Y; Sun Y; Fu Q; Wang L
Hepatobiliary Surg Nutr; 2023 Oct; 12(5):671-681. PubMed ID: 37886198
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
[TBL] [Abstract][Full Text] [Related]
4. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
[TBL] [Abstract][Full Text] [Related]
5. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
6. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
7. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.
Chen J; Dan L; Tu X; Sun Y; Deng M; Chen X; Hesketh T; Li R; Wang X; Li X
Hepatol Int; 2023 Feb; 17(1):202-214. PubMed ID: 36194337
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
Kim KS; Hong S; Ahn HY; Park CY
Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
[TBL] [Abstract][Full Text] [Related]
10. Extrahepatic malignancies in metabolic dysfunction-associated fatty liver disease: A nationwide cohort study.
Park MK; Hur MH; Moon HS; Shin H; Chung SW; Won S; Lee YB; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
Liver Int; 2024 Mar; 44(3):799-810. PubMed ID: 38230848
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
13. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
[TBL] [Abstract][Full Text] [Related]
14. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
18. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
[TBL] [Abstract][Full Text] [Related]
20. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]